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INTRODUCTION
Anxiety disorders are among the most prevalent of psychiatric illnesses, which has led to the search for their neurobiological bases as well as molecular targets for anxiolytic drug development. The limbic system and the hypothalamic-pituitary-adrenal axis are important mediators of anxiety and responses to stress (Chrousos and Gold, 1992; Ray et al., 1993) . Exposure to aversive stimuli produces numerous physiological and behavioral effects in animals, including changes in endocrine function, food intake, body weight, body temperature, and goal-oriented behaviors (Dallman et al., 1992; Lang et al., 2000) . Recent work has suggested that cGMP signaling may be involved in anxiety-related behavior (Masood et al., 2008) .
Cyclic GMP formed by the action of the soluble isoform of guanylyl cyclase is hydrolyzed by enzymes of the PDE super-family. Twenty-one PDE genes have been identified and classified into eleven families. Phosphodiesterase-2 (PDE2), a cGMPstimulated PDE, is a 105-kD homodimer that exists in particulate and soluble forms.
Although cGMP is the preferred substrate and effector molecule for this enzyme, PDE2 hydrolyzes both cGMP and cAMP with positively cooperative kinetics. At physiological concentrations of cyclic nucleotides, PDE2 responds to elevated cGMP with increased hydrolysis of cAMP (Manganiello et al., 1990) . Therefore, PDE2 may be a link between cAMP-and cGMP-mediated signaling mechanisms (Hajjhussein et al., 2007) .
PDE2 is highly expressed in the brain and adrenal gland (Boess et al., 2004; Nikolaev et al., 2005) . A reduction in PDE2 activity through pharmacological inhibition of this enzyme would result in an increase in cGMP that could influence anxiety/stressrelated events. Consistent with this, it has been found that Bay 60-7550, a selective This article has not been copyedited and formatted. The final version may differ from this version. 
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5 inhibitor of PDE2, prevents the neurochemical and anxiogenic-like behavioral effects of oxidative stress in mice through a cGMP-mediated process (Masood et al., 2008) . This may have relevance to neuropsychiatric disorders that involve oxidative stress (Gingrich, 2005) .
Nitric oxide (NO) has been implicated in neuroprotective and pathological states, including those involved in anxiety and responses to stress (Tippeswamy et al., 2001; Moncada et al., 1991) . NO is generated through nitric oxide synthase (NOS), which can be activated by Ca 2+ influx through N-methyl-D-aspartate (NMDA) receptors on neurons.
Pharmacological studies suggest that NO plays a role in anxiety and stress-related processes. Intra-amygdalar or intra-hippocampal administration of N(G)-nitro-L-arginine methyl ester (L-NAME), a NOS inhibitor, induces anxiogenic effects in rats in the elevated plus-maze (Monzon et al., 2001) . By contrast, L-arginine, an NO donor, produces anxiolytic effects, suggesting an anti-stress profile for NO in the central nervous system (Masood et al., 2003 (Masood et al., , 2004 . Also, mice deficient in cyclic cGMP kinase (i.e., cGKII), a downstream mediator of cGMP, exhibit an anxiogenic behavioral profile (Werner et al., 2004) . Finally, inhibition of NOS, which reduces cGMP signaling, attenuates the behavioral effects of the benzodiazepine chlordiazepoxide (Elfline et al., 2004) . Overall, these data suggest a role for NO-cGMP signaling in anxiety.
The present study investigated the effects of PDE2 inhibition on anxiety-related behaviors and responses to stress and assessed the involvement of cGMP signaling in their actions. The effects of two selective PDE2 inhibitors, Bay 60-7550 and ND7001, as well as NO modulators, were tested using anxiety-related behavioral models with stressed and non-stressed mice. Further, neurochemical measures were obtained to determine the 
Drug treatments
Bay 60-7550 (0.5, 1, and 3 mg/kg), ND7001 (0.5, 1.0 and 3 mg/kg), detanonoate (0.5 mg/kg), L-NAME (50 mg/kg), or diazepam (1 mg/kg) was administered after restraint stress and 30 min prior to behavioral testing. Mice also were treated with Bay 60-7550 (3 mg/kg), ND7001 (3 mg/kg), detanonoate, (0.5 mg/kg), L-NAME (50 mg/kg), or diazepam (1 mg/kg) in the absence of restraint stress; drugs were administered 30 min before the behavioral tests. Bay 60-7550 shows 50-fold selectivity for PDE2 compared with PDE1, 100-fold compared with PDE5, and greater than 200-fold compared with the other PDE families (Boess et al., 2004) . ND7001 exhibits at 1east 100-fold selectivity This article has not been copyedited and formatted. The final version may differ from this version. Cheng and Prusoff (1973) .
Measurement of cGMP and cAMP in neuronal cultures
Primary cultures of rat cerebral cortical neurons were prepared from the brains of newborn male and female rat pups as described previously (Masood et al., 2008; Suvarna This article has not been copyedited and formatted. The final version may differ from this version. atmosphere. On day 3, the media was replaced with fresh DMEM containing 10 µM β -cytosine arabinoside to diminish glial cell proliferation. On day 5, the β -cytosine arabinoside-containing media was aspirated, and regular DMEM was added to the cells.
The cells were grown for seven more days before they were used on day 12 for cGMP and cAMP assays.
The cells were rinsed and then incubated for 50 min at 37°C in HEPES buffer (140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl 2 , 100 nM glycine, 15 mM glucose, and 25 mM HEPES, pH 7.4) containing 1 µM tetrodotoxin. PDE2 inhibitors, MK-801, and L-NAME were added 10 min before the addition of NMDA or detanonoate. Fifteen minutes after the addition of NMDA or detanonoate, the cells were scraped into 100 μ l of 0.1N ice-cold hydrochloric acid. The cell preparations were then sonicated and centrifuged at 13,000 g for 50 minutes at 4°C. Cyclic AMP and cGMP in supernatant were measured by ELISA (Assay Designs, Ann Arbor, MI) and normalized to protein content (Smith et al., 1985 ; Bio-Rad Laboratories, Hercules, CA).
Behavioral testing
Anxiogenic and anxiolytic effects on behavior were assessed using the elevated plus-maze, hole-board, and open-field; these tests have been shown to be sensitive to anxiolytic drugs from different pharmacological classes (Cryan and Holmes, 2005) .
Behavioral measures (see below) were recorded by a trained observer who was unaware of the treatment condition. Each behavioral test was carried over a period of 2-3 days, with treatments assessed in a random manner.
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Hole-board
The hole-board test was conducted as described previously; anxiolytic effects were inferred from increases in the number of head-dips and the time spent head-dipping (Masood et al., 2008) . The hole-board apparatus consisted of a Perspex box (60 cm × 60 cm × 35 cm) with four equidistant holes 4 cm in diameter in the floor. For the hole-board experiments, each animal was placed in the center of the hole-board and allowed to freely explore the apparatus for 5 min. The number of head-dips and total time spent in headdipping were recorded.
Open-field
The open-field test was conducted as described previously; anxiolytic effects were inferred from a decrease in entry latency, i.e., the time to leave the start square and enter This article has not been copyedited and formatted. The final version may differ from this version. 
Statistical analysis
Data are expressed as means ± SEM. Data for the effects of each drug treatment, which were normally distributed, were analyzed by one-way analysis of variance followed by Bonferroni's post-hoc tests. A p value < 0.05 was considered statistically significant.
This article has not been copyedited and formatted. The final version may differ from this version. cultures [F (6,14) =3.31, p<0.05], post-hoc analysis showed that ND7001 (10 μ M) did not increase cAMP, either alone or in combination with NMDA ( Fig. 1) . NMDA or MK-801, alone or in combination, did not produce any effect on cGMP or cAMP levels.
Effects of PDE2 inhibitors on NO donor-stimulated cGMP in neuronal cultures
PDE2 inhibitors and NO modulators were evaluated for their effects on cGMP in neuronal cultures (Fig. 2) (Fig. 3) .
The effects of the benzodiazepine anxiolytic drug diazepam on behavior in the elevated plus-maze in both stressed and non-stressed mice were similar to those of the PDE2 inhibitors (Fig. 3 ).
Overall analysis of the effects of NO-modulating drugs and PDE2 inhibitors
showed that percentages open-arm entries and time were significantly different across treatment conditions [F(5, 30)=12.3 and F(5, 30)=11.76, p<0.01, respectively]. The NO donor detanonoate (0.5 mg/kg), which like the PDE2 inhibitors increases cGMP signaling, produced an anxiolytic-like effect in the elevated plus-maze in stressed, but not non-stressed, mice (Table 1) ; the effects of detanonoate tended to be enhanced by cotreatment with the PDE2 inhibitors. By contrast, the NOS inhibitor L-NAME (50 mg/kg) produced an anxiogenic effect in non-stressed mice, but did not alter behavior in mice subjected to restraint stress (Table 1) .
For all of the tests, total arm entries did not differ significantly among the treatment groups compared to their respective controls (data not shown).
This article has not been copyedited and formatted. The final version may differ from this version. Restraint stress reduced the number of head-dips and time spent head-dipping in the holeboard test compared to the non-stressed condition, indicative of an anxiogenic effect (Fig.   4 ). The PDE2 inhibitors Bay 60-7550 (1 mg/kg) and ND7001 (1 mg/kg) reversed the effects of restraint stress on the number of head-dips and time spent head-dipping.
In non-stressed mice, Bay 60-7550 increased, in a dose-dependent manner, the number of head-dips and time spent head-dipping, compared to vehicle-treated mice; significant increases were observed at doses of 1 and 3 mg/kg (Fig. 4) . At a dose of 1 mg/kg, ND7001 increased the number of head-dips in non-stressed mice, but did not affect time of head-dipping.
Diazepam (1 mg/kg) increased the number of head-dips and time spent headdipping in the hole-board test in stressed mice and increased the number of head-dips in non-stressed mice (Fig 4) .
Overall analysis of the effects of NO-modulating drugs and PDE2 inhibitors
showed that number of head-dips and time spent head-dipping were significantly different across treatments [F(5,30)=7.71 and F(5,30)=8.9, p<0.01, with and without restraint stress, respectively]. The NO donor detanonoate (0.5 mg/kg) produced an anxiolytic-like effect in the hole-board test in stressed, but not non-stressed, mice (Table   This article inhibitors. By contrast, L-NAME (50 mg/kg) produced an anxiogenic effect in nonstressed mice, but did not alter behavior in mice subjected to restraint stress (Table 1) .
Open-field
Overall analysis of open-field data showed that entry latency, ambulation, and the open-field test in both stressed and non-stressed mice (Table 1) ; the effects of detanonoate tended to be enhanced by co-treatment with the PDE2 inhibitors. By contrast, L-NAME (50 mg/kg) tended to produce an anxiogenic effect in non-stressed mice (only the effect on ambulation was significant), but did not alter behavior in mice subjected to restraint stress (Table 1) .
Effects of the guanylyl cyclase inhibitor ODQ on the anxiolytic effects of Bay 60-7550 and ND7001
Overall analysis showed that the guanylyl cyclase inhibitor ODQ (20 mg contribute to differential effects of PDE2 inhibitors in the presence and absence of restraint stress (Watanabe et al., 2002; Pollack et al, 1991) .
Bay 60-7550 and ND7001 also tended to enhance the behavioral effects of the NO donor detanonoate. The anxiolytic effects likely result from enhanced NO-cGMP signaling since PDE2 inhibition is known to increase cGMP (Suvarna and O'Donnell, 2002) , while detanonoate increases NO, which activates guanylyl cyclase, leading to an increase in cGMP (Cary et al., 2006) . Consistent with this, it has been reported that mice deficient in cGMP-dependent protein kinase (i.e., cGKII), a mediator of the intracellular actions of cGMP, exhibit an anxiogenic-like behavioral phenotype (Werner et al., 2004 ).
This kinase is highly expressed in cerebral cortex, basal forebrain, and amygdala, regions thought to be important regulators of emotionality. A previous study has reported that pretreatment with a cGMP PDE inhibitor antagonizes the anxiogenic effect of 15% N 2 O and enhances the anxiolytic effect of 25% N 2 O, implying that cGMP reduces anxiety (Li et al., 2004) . Further, inhibition of NOS attenuates the behavioral effects of chlordiazepoxide, which suggests some role for cGMP signaling in the mediation of the behavioral effects of benzodiazepine anxiolytics (Elfline et al., 2004) . Another report also points to the importance of NO-cGMP signaling in controlling emotionality (Li et al., 2005) .
The NOS inhibitor L-NAME produced anxiogenic effects on behavior in nonstressed mice. However, it did not produce an additive anxiogenic effect in mice exposed to restraint stress. This may be due to fact that restraint stress itself had pronounced effects on behavior, precluding any additional effect of L-NAME. Also, since it has been reported that restraint leads to a decrease in NO levels in brain (Masood et al, 2004) , blocking NOS with L-NAME in mice exposed to restraint stress may not lead to a further decrease in NO activity. In contrast to NOS inhibition, the NO donor detanonoate reversed the anxiogenic effects of restraint stress in mice but did not produce an anxiolytic effect on its own. Given that PDE2 inhibitors were effective, at least to some degree, in non-stressed mice, this suggests that PDE2 inhibition may produce greater or more targeted increases in cGMP signaling.
The present study showed that inhibiting cGMP synthesis using the guanylyl cyclase inhibitor ODQ reversed the anxiolytic effects of the PDE2 inhibitors Bay 60-7550 and ND7001; in the hole-board test ODQ produced an anxiogenic effect on its own.
ODQ also antagonizes the effect of PDE2 inhibition on cGMP signaling in neurons (Suvarna and O'Donnell, 2002) . These data indicate that the anxiolytic effects of PDE2 inhibitors depend on increased cGMP signaling. Further studies will be required to evaluate the relative importance of the effects of PDE2 inhibitors on downstream protein kinases, phosphoproteins, and cGMP-regulated ion channels that may mediate the behavioral effects.
Bay 60-7550 also has been shown to enhance memory (Boess et al., 2004; Rutten et al., 2007) ; this may result from the involvement of PDE2 in NMDA receptor-mediated signaling in the hippocampus (Suvarna and O'Donnell, 2002) . This effect of Bay 60-7550 contrasts with those of benzodiazepine anxiolytics, which have deleterious effects on memory (Hu et al., 2006) . Thus, PDE2 inhibitors, in contrast to benzodiazepines, may be able to exert anxiolytic effects without impairing memory. It remains to be determined whether the potential abuse liability of PDE2 inhibitors is favorable to those of benzodiazepines.
This article has not been copyedited and formatted. The final version may differ from this version. Previous work also has shown that Bay 60-7550 reverses the anxiogenic effects on behavior produced by oxidative stress while diazepam has little effect under these conditions (Masood et al., 2008) . Therefore, while PDE2-mediated increases in cGMP signaling may reverse both oxidative stress-and emotional stress-related anxiogenic behavioral effects, benzodiazepines may exhibit a somewhat different profile of effectiveness. Since long-term use of benzodiazepines in the treatment of generalized anxiety disorder and panic disorders is limited due to tolerance and dependence phenomena, studies examining the longer-term effects of PDE2 inhibitors are warranted.
NO has been shown to play a crucial role in central nervous system function (Zhang and Snyder, 1995) . In the present study, the NO donor detanonoate mimicked the anxiolytic effects of diazepam in the three behavioral tests, while the NOS inhibitor L-NAME produced behavioral effects similar to those observed following restraint stress.
These effects of NO donors and inhibitors are consistent with the results of earlier studies (Masood et al., 2003; Monzon et al., 2001; De Olieviera et al., 1997; Vale et al., 1998) .
Both Bay 60-7550 and ND7001 increased cGMP in primary neuronal cultures.
This was evident both for basal and NMDA-stimulated cGMP levels. Similarly, the NO donor detanonoate increased the levels of cGMP in neuronal cultures; this effect was enhanced by co-treatment with Bay 60-7550 or ND7001. These data, when considered in light of the ODQ antagonism data, suggest that anxiolytic effects on behavior can be achieved either by enhancing cGMP synthesis by increasing NO or by reducing cGMP degradation by inhibiting its hydrolysis by PDE2 (Masood et al., 2003 (Masood et al., , 2008 (Iffland et al., 2005 ), this appears to be an area ripe for drug discovery and development efforts.
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